Skin cancer: Drug gives '40% melanoma survival'

Four-in-10 patients with a deadly skin cancer were still alive after three years when given a drug to boost their immune system, a study suggests.

The trial gave 655 patients with melanoma the drug pembrolizumab, which stops cancers evading the immune system's assault.

The data, released ahead of the world's biggest cancer conference, also showed 15% of patients had no sign of cancer.

Experts said the findings were exciting and "really a step forward".

Full Story